Related references
Note: Only part of the references are listed.Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy
F. Fernandez et al.
PHARMACOGENOMICS (2007)
Recent advances in the pharmacogenomics of pain and headache
P. Montagna
NEUROLOGICAL SCIENCES (2007)
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
David W. Dodick et al.
CNS DRUGS (2007)
Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine:: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials
CG Dahlöf et al.
CEPHALALGIA (2006)
Pharmacogenetics of headache treatment
P Montagna et al.
NEUROLOGICAL SCIENCES (2005)
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
PHARMACOGENOMICS JOURNAL (2005)
Adverse drug reactions: role of pharmacogenomics
G Severino et al.
PHARMACOLOGICAL RESEARCH (2004)
Codeine intoxication associated with ultrarapid CYP2D6 metabolism
Y Gasche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular diversity at the CYP2D6 locus in the Mediterranean region
S Fuselli et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2004)
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms
DW Dodick et al.
CEPHALALGIA (2004)
Moving towards individualized medicine with pharmacogenomics
WE Evans et al.
NATURE (2004)
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein
DC Evans et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan
M Salva et al.
DRUG METABOLISM AND DISPOSITION (2003)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Genomic medicine - Inheritance and drug response.
R Weinshilboum
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Triptans (serotonin, 5-HT1B/1D agonists) in migraine:: detailed results and methods of a meta-analysis of 53 trials
MD Ferrari et al.
CEPHALALGIA (2002)
How does almotriptan compare with other triptans?: A review of data from placebo-controlled clinical trials
CGH Dahlöf et al.
HEADACHE (2002)
Advances in pharmacological treatment of migraine
HC Diener et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist:: differential effects of propranolol, nadolol and metoprolol
MR Goldberg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
